TP53 and Pleural effusion: Additionally, a study by Marazioti et al. [47] demonstrated, in a mouse model, that KRAS point mutations in epitheliod MPM, with or without TP53 alteration, are potentially able to drive MPM development and a more aggressive disease with frequent mesothelial pleural effusion.